Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Taiwan Liposome Company, Ltd. TLC NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • TW • USD

SharesGrow Score
41/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Taiwan Liposome Company, Ltd. (TLC) is a Biotechnology company in the Healthcare sector, currently trading at $7.00. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Financials: revenue is $102M, +70%/yr average growth. Net income is $983M (loss), growing at -4.8%/yr. Net profit margin is -964.7% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $667M against $438M equity (Debt-to-Equity (D/E) ratio 1.52, leveraged). Current ratio is 4.11 (strong liquidity). Debt-to-assets is 38.1%. Total assets: $1.7B.

Analyst outlook: 4 / 5 analysts rate TLC as buy (80%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 54/100 (Partial), Future 90/100 (Pass), Income 10/100 (Fail).

TLC SharesGrow Score Overview

49/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 54/100
Gross margin is + market cap
FUTURE 90/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TLC

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
TLC: +70%/yr revenue is, -4.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet TLC: Debt-to-Equity (D/E) ratio 1.52 (leveraged), Current ratio is 4.11 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
54/100
TLC: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 54/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
90/100
Analyst outlook: 4 / 5 analysts rate TLC as buy (80%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
TLC: Net profit margin is -964.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range7-7.09
Volume12.42K
Avg Volume (30D)17.61K
Beta (1Y)0.80
Share Statistics
EPS (TTM)-24.89
Shares Outstanding$39.51M
IPO Date2018-11-21
CEOKeelung Hong
Financial Highlights & Ratios
Revenue (TTM)$101.93M
Gross Profit$101.93M
EBITDA$-909.66M
Net Income$-983.31M
Operating Income$-983.11M
Total Cash$1.34B
Total Debt$667.38M
Net Debt$-675.28M
Total Assets$1.75B
Price / Earnings (P/E)-0.3
Analyst Forecast
Rating ConsensusBuy
Analysts Covering5
Buy 80% Hold 20% Sell 0%
Company Info
CountryTW
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS8740381020

Price Chart

Track all markets on TradingView
TLC
Taiwan Liposome Company, Ltd. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
7.00 52WK RANGE 7.09

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message